Comparing the current results to its competitors, Alx Oncology Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 36.92 %, recorded in the same quarter.
Alx Oncology Holdings Inc's Comment on Competition and Industry Peers
The competitive landscape includes companies developing antibody drug conjugates targeting EGFR, notably Bristol Myers Squibb with Systimmune, CSPC, and Henlius. Additional competitors comprise academic institutions, government agencies, and other public and private research organizations engaged in research, patent protection, and collaborative efforts related to research, development, manufacturing, and commercialization. Many competitors possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger firms. Competition extends to recruiting and retaining qualified personnel, establishing clinical trial sites, enrolling subjects, and acquiring complementary technologies. The company’s commercial opportunities may be limited if competitors develop products that are safer, more effective, more convenient, or less expensive.
December 10, 2024
: In recent months, ALX Oncology has reported significant advancements in its investigational CD47-blocker, evorpacept. These findings, spanning multiple clinical trials, hint at a transformative potential in the treatment of a variety of cancers. As the company continues to push the boundaries of immuno-oncology, the implications for both cancer therapy and ALX Oncology s trajectory are profound.ALX Oncology, a clinical-stage biotechnology company, has been at the forefront of developing therapies that exploit the immune system s capabilities to treat cancer. Central to their advances is the investigational therapy, evorpacept, a CD47-blocker designed to improve the immune system s ability to destroy cancer...
Publicly Traded Peers of Alx Oncology Holdings Inc
Zymeworks Inc Share Performance
+10.47%
This Quarter
Zymeworks Inc
Profile
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Alx Oncology Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alx Oncology Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
